Bard prepares for rapid expansion

Article Excerpt

C.R. BARD INC. $139 (New York symbol BCR; Conservative Growth Portfolio, Consumer sector; Shares outstanding: 77.9 million; Market cap: $10.8 billion; Price-to-sales ratio: 3.7; Dividend yield: 0.6%; TSINetwork Rating: Above Average; www.crbard.com) makes vascular products, such as stents and catheters (29% of its 2012 sales); oncology products that detect and treat various types of cancer (27%); urology products, such as drainage and incontinence devices (26%); and surgical tools and other products (18%). The company mainly makes single-use, disposable products, so customers must continually buy new ones. As a result, Bard’s sales rose 20.6%, from $2.5 billion in 2008 to $3.0 billion in 2012. Earnings improved by 24.1%, from $455.4 million in 2008 to $565.3 million in 2012. The company is an aggressive buyer of its own stock, so per-share earnings jumped 48.0%, from $4.44 to $6.57. New strategy sends stock higher The shares have gained 42% since the start of 2013. That’s partly in response to the company’s new long-term growth plan, which…